1. Volume 73, Issue 4, Pages e116-e118 (April 2018)
Erratum to “CheckMate 025 Randomized Phase 3 Study: Outcomes by Key Baseline Factors and Prior Therapy for Nivolumab Versus Everolimus in Advanced Renal Cell Carcinoma” [Eur Urol 2017;72:962–71] 
Bernard Escudier, Padmanee Sharma, David F. McDermott, Saby George, Hans J. Hammers, Sandhya Srinivas, Scott S. Tykodi, Jeffrey A. Sosman, Giuseppe Procopio, Elizabeth R. Plimack, Daniel Castellano, Howard Gurney, Frede Donskov, Katriina Peltola, John Wagstaff, Thomas C. Gauler, Takeshi Ueda, Huanyu Zhao, Ian M. Waxman, Robert J. Motzer 
European Urology 
Volume 73, Issue 4, Pages e116-e118 (April 2018)
DOI: /j.eururo
Copyright © Terms and Conditions

2. Fig. 1A
correct version published in the updated online article in December 2017–Forest plot of overall survival by baseline characteristics (risk group, age group, number and sites of metastases, prior therapy). CI=confidence interval; IL-2=interleukin-2; IMDC=International Metastatic Renal Cell Carcinoma Database Consortium; MSKCC=Memorial Sloan Kettering Cancer Center; ORR=overall response rate; OS=overall survival.
European Urology  , e116-e118DOI: ( /j.eururo )
Copyright © Terms and Conditions

3. Fig. 1A
incorrect version as printed and originally published online–Forest plot of overall survival by baseline characteristics (risk group, age group, number and sites of metastases, prior therapy). CI=confidence interval; IL-2=interleukin-2; IMDC=International Metastatic Renal Cell Carcinoma Database Consortium; MSKCC=Memorial Sloan Kettering Cancer Center; ORR=overall response rate; OS=overall survival.
European Urology  , e116-e118DOI: ( /j.eururo )
Copyright © Terms and Conditions